Inovio Pharmaceuticals Inc. (INO) Given Average Rating of “Buy” by Analysts
Inovio Pharmaceuticals Inc. (NASDAQ:INO) has earned an average rating of “Buy” from the eight brokerages that are covering the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $17.85.
INO has been the topic of a number of recent research reports. Stifel Nicolaus restated a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a report on Sunday, July 17th. Maxim Group restated a “buy” rating and set a $14.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, June 21st. Rodman & Renshaw restated a “buy” rating and set a $17.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, June 21st. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, June 21st. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Tuesday, July 19th.
In other Inovio Pharmaceuticals news, COO Niranjan Sardesai sold 21,800 shares of the firm’s stock in a transaction on Monday, August 29th. The shares were sold at an average price of $9.30, for a total value of $202,740.00. Following the sale, the chief operating officer now directly owns 70,234 shares in the company, valued at approximately $653,176.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 9.90% of the stock is currently owned by company insiders.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/inovio-pharmaceuticals-inc-ino-given-average-rating-of-buy-by-analysts.html
Hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its stake in shares of Inovio Pharmaceuticals by 43.4% in the second quarter. PNC Financial Services Group Inc. now owns 34,566 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 10,466 shares during the period. GSA Capital Partners LLP raised its stake in shares of Inovio Pharmaceuticals by 172.4% in the second quarter. GSA Capital Partners LLP now owns 69,200 shares of the biopharmaceutical company’s stock valued at $639,000 after buying an additional 43,800 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of Inovio Pharmaceuticals by 11.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 26,730 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 2,768 shares during the period. DekaBank Deutsche Girozentrale raised its stake in shares of Inovio Pharmaceuticals by 34.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 10,500 shares during the period. Finally, Emerald Acquisition Ltd. acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at $2,181,000. Institutional investors and hedge funds own 28.59% of the company’s stock.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded down 5.27% during midday trading on Monday, hitting $8.09. 1,029,465 shares of the stock were exchanged. The firm’s market cap is $595.00 million. Inovio Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $11.69. The stock’s 50 day moving average is $9.25 and its 200 day moving average is $9.61.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $6.20 million for the quarter, compared to the consensus estimate of $4.95 million. Inovio Pharmaceuticals had a negative net margin of 88.19% and a negative return on equity of 22.29%. The firm’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.09) EPS. On average, equities research analysts forecast that Inovio Pharmaceuticals will post ($0.93) earnings per share for the current fiscal year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.